CLIMB: using scans and tissue biomarkers to learn more about primary CNS lymphoma
Official title: A Prospective Imaging and Translational Tissue Study in CNS Lymphoma to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
Run by Royal Marsden NHS Foundation Trust · NCT05828628 · Data updated 2026-11-12
This project will try to use brain scans and tumour tissue from adults with newly diagnosed primary CNS lymphoma to find markers that predict treatment response and time without disease progression.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Locations | 1 site (Sutton) |
| Status | Recruiting |
| Started | September 18, 2023 |
| Main results expected | September 2028 |
| Study ends | September 2031 |
| Registry record updated | June 11, 2025 |
| Trial ID | NCT05828628 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with a radiological or histological diagnosis of primary CNS lymphoma who have not received prior CNS-directed therapy (steroid use allowed) and who can consent or have an appropriate consultee/legal representative.
✕Probably not a fit
Patients with lymphoma outside the CNS are excluded and are unlikely to benefit from findings specific to primary CNS lymphoma, and those who have already had CNS-directed therapy are not eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
CLIMB is a single-centre prospective imaging and translational tissue programme run at The Royal Marsden. It will recruit adults with newly diagnosed primary CNS lymphoma who have not yet received CNS-directed therapy. Participants will provide tumour tissue for molecular analysis and undergo standardized imaging with response assessments using CCA to correlate imaging and molecular findings with progression-free survival. The study aims to identify candidate predictive and prognostic biomarkers that could guide future trials and clinical decision-making.
Why it matters
Potential benefit: If successful, the work could help doctors predict which patients are likely to respond to treatment and better estimate how long patients may remain progression-free.
How similar studies have gone: Previous research has suggested that imaging features and tissue biomarkers can be informative in CNS lymphoma, but validated predictive and prognostic markers remain limited, so this approach is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects capable of giving informed consent, or if appropriate, if subject's capacity is deemed limited due to CNS involvement, a consultee can provide consent on their behalf. Some patients with PCNSL may be incapable of providing their own consent due to the neurological effects of their disease. In these cases the patient will be classed as an incapacitated adult and a legal representative will be sought in accordance with English or Scottish law as applicable (see 7.2.1) * A radiological or histological diagnosis of primary CNS lymphoma. * Have not received prior CNS directed therapy. Prior use of steroids is permitted. * Participants aged ≥18 years old. Exclusion Criteria: \- Involvement of lymphoma outside of the CNS
Where it's running
-
The Royal Marsden NHS Foundation Trust, Downs Road
Sutton, United Kingdom Recruiting
Study contacts
- Principal investigator: Ian Chau — Royal Marsden NHS Foundation Trust
- Study coordinator: GI and Lymphoma Unit
- Email: GI.Trials@rmh.nhs.uk
- Phone: 02086426011
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment of relapsed CNS large B-cell lymphoma with Relma-cel and Tislelizumab
This study is testing a new treatment combining a cellular therapy and an immunotherapy for people with relapsed central nervous system large B-cell lymphoma to see if it helps them feel better and live longer.
-
Zanubrutinib combined with chemotherapy for patients with secondary CNS lymphoma
This study is testing if a new combination of medications, including Zanubrutinib and chemotherapy, can help people with secondary Central Nervous System lymphoma feel better and improve their health.
-
T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma
This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.
-
Treatment of CNS lymphoma using targeted endoradiotherapy
This study is testing a new treatment for patients with recurrent or hard-to-treat central nervous system lymphoma to see if it is safe and effective.
-
Combination treatment of Tafasitamab and Lenalidomide for relapsed CNS lymphoma
This study is testing a combination of two drugs, Tafasitamab and Lenalidomide, to see if they can help people with relapsed central nervous system lymphoma feel better and improve their treatment outcomes.
-
Testing a new CAR T cell therapy for adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma
This study is testing a new CAR T cell therapy to see if it can help adolescents and adults with relapsed B-cell Non-Hodgkin Lymphoma feel better and improve their chances of recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.